retatrutide safety profile VisualAbstract: reduces body weight by 17.5% in patients with obesity Full article: Efficacy and safety

Since the FDA approved the first GLP-1 medicationByetta (exenatide)in 2005, clinicians have observed that GLP-1s not only support blood sugar control but also contribute to weight loss and other metabolic health improvements

Targeting the GIPR for obesity: to agonize or antagonize

The result: a medication built on the same active pharmaceutical ingredient - semaglutide - but operating in a completely different regulatory category

The chart below is an educational example based on commonly discussed Retatrutide dose levels in research settings

The most common retatrutide side effects are nausea (28%), diarrhea (24%), constipation (21%), and vomiting (17%), with symptoms peaking around weeks 6-8 before substantially improving by week 12

Its attention to detail in user experience and its ability to handle projects of any size make it a top choice for project management